Clinical applications

 

 

 

Diseases where benefit of endocan testing is clinically proven :

 

Predicted event Target diseases When testing Decisionnal value Time to event Possible decision making PubMed source
Acute respiratory distress syndrome Polytrauma, Severe sepsis, Septic shock At ICU admission < 5 ng/mL in plasma 48-72h Lung protective ventilation, Corticosteroids PubMed
Severity Community-acquired pneumoniae At emergency room admission Undetermined Undetermined Sorting PubMed
Early recurrence Hepatocarcinoma suspicion At diagnosis time Positive biopsy Till surgery Enlarged resection, Response to therapy PubMed
Aggressiveness Gastric cancer At diagnosis time Positive biopsy Till surgery Enlarged resection, Response to therapy PubMed

 

Diseases where endocan testing can be benefit :

 

Predicted event Target diseases When testing Decisionnal value Time to event Possible decision making PubMed source
Preeclampsia Pregnancy End of first trimester < 0.5 ng/mL in plasma 8 to 12 weeks Anti-oxydants, Aspirin PubMed
Digestive graft versus host disease Allogeneic stem cell transplantation Before transplantation <1.5 ng/mL Till transplantation Undetermined PubMed
Systemic inflammatory Response Syndrome Cardiac surgery After/before surgery Ratio < 3 in plasma 48-72h Anti-inflammatory drugs PubMed
Active retinopathy Diabetic retinopathy Before local antiangiogenic therapy > 1 ng/mL in vitreous Undetermined Response to therapy PubMed
Bad prognosis Cirrhosis At diagnosis time > 5 ng/mL in plasma Undetermined Response to therapy PubMed
Severity Atherosclerosis At diagnosis time Undetermined Undetermined Undetermined PubMed
Bad prognosis Lung cancer At diagnosis time > 1,3 ng/mL in plasma Undetermined Response to therapy PubMed
Sévérité Sleep apnea syndrome At diagnosis time > 1 ng/mL in plasma Undetermined Response to therapy PubMed